Showing results (2101-2110 of 2,378) with videos related to
Sort By:
Pageof 238
Cancer Chemotherapy and Pharmacology|September 29, 1999
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationD A Rinaldi, J G Kuhn, H A Burris, et al.European Heart Journal. Acute Cardiovascular Care|November 3, 2017
Predictors of survival and ability to wean from short-term mechanical circulatory support device following acute myocardial infarction complicated by cardiogenic shockA Reshad Garan, Christina Eckhardt, Koji Takeda, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 17, 2015
Neonatal High Bone Mass With First Mutation of the NF-κB Complex: Heterozygous De Novo Missense (p.Asp512Ser) RELA (Rela/p65)Anja L Frederiksen, Martin J Larsen, Klaus Brusgaard, et al.American Journal of Clinical Oncology|August 3, 2005
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancersGhassan K Abou-Alfa, Eric K Rowinsky, Yehuda Z Patt, et al.Cancer Chemotherapy and Pharmacology|November 22, 2007
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male miceLaura K Zerbe, Lori D Dwyer-Nield, Jason M Fritz, et al.Science (New York, N.Y.)|June 9, 2007
Attenuation of allergic contact dermatitis through the endocannabinoid systemMeliha Karsak, Evelyn Gaffal, Rahul Date, et al.BMC Genomics|December 19, 2015
An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancerKaren A Ryall, Jihye Kim, Peter J Klauck, et al.Thrombosis and Haemostasis|November 20, 2015
The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitorsAlice S van Velzen, Corien L Eckhardt, Nina Streefkerk, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRPE K Rowinsky, L Smith, Y M Wang, et al.Plos One|May 1, 2020
Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational researchJose Rodrigo Espinosa Fernandez, Bedrich L Eckhardt, Jangsoon Lee, et al.Pageof 238